| Literature DB >> 29119218 |
Jens G Klinzing1,2, Sabine Kugler3, Surjo R Soekadar4, Björn Rasch5, Jan Born3,6, Susanne Diekelmann3.
Abstract
RATIONALE: Sleep-dependent memory consolidation depends on the concerted reactivation of memories in the hippocampo-neocortical system. The communication of reactivated information from the hippocampus to the neocortex is assumed to be enabled by low levels of acetylcholine, particularly during slow-wave sleep (SWS). Recent studies suggest that the reactivation of memories does not only occur spontaneously but can also be externally triggered by re-presenting learning-associated cues during sleep.Entities:
Keywords: Acetylcholine; Memory consolidation; Odor reactivation; Physostigmine; Sleep
Mesh:
Substances:
Year: 2017 PMID: 29119218 PMCID: PMC5748395 DOI: 10.1007/s00213-017-4768-5
Source DB: PubMed Journal: Psychopharmacology (Berl) ISSN: 0033-3158 Impact factor: 4.530
Fig. 1Experimental design. In the evening, all subjects learned a 2D object-location task under the presence of an odor. Starting at subsequent sleep onset, subjects received either an acetylcholine-esterase inhibitor (physostigmine group) or saline solution (placebo group) intravenously for 40 min. During the first 20 min of SWS, the learning-associated odor was presented again in one night (odor condition) and an odorless vehicle in the other night (vehicle condition). After a sleep period of ~ 40 min, subjects were woken up and watched a movie to allow for the effects of the drug to fade out. Subjects then learned an interference memory task and were finally tested on their recall of the original memory task
Fig. 2Memory performance after odor cueing under physostigmine. Odor cueing during SWS improved memory performance as compared to vehicle, independent of physostigmine administration (“odor/vehicle” main effect: p = 0.026). Top bars show the means ± s.e.m. of memory performance at final recall relative to the learning performance (with learning set to 100%) in the odor and vehicle conditions of the physostigmine and placebo groups, respectively. Small bottom bars show each participant’s performance difference between the odor and vehicle conditions, with positive values corresponding to better performance in the odor condition and negative values corresponding to better performance in the vehicle condition
Performance in the visuo-spatial memory task
| Physostigmine | Placebo | |||
|---|---|---|---|---|
| Odor | Vehicle | Odor | Vehicle | |
| Learning performance | 10.40 ± 0.27 | 10.80 ± 0.46 | 9.64 ± 0.25 | 10.29 ± 0.35 |
| Learning trials | 2.47 ± 0.31 | 2.13 ± 0.35 | 2.57 ± 0.42 | 2.43 ± 0.42 |
| Recall performance | 6.67 ± 0.67 | 5.93 ± 0.50 | 6.14 ± 0.39 | 5.07 ± 0.45 |
| Interference learning | 8.53 ± 0.92 | 8.33 ± 0.81 | 7.93 ± 0.84 | 7.43 ± 0.82 |
Learning performance (absolute number of cards recalled in the last learning trial), learning trials (repetitions needed to reach learning criterion), recall performance (absolute number of cards correctly indicated at final recall), and interference learning performance (number of cards recalled during immediate recall of the interference task) for each experimental group and condition (means ± s.e.m.)
Sleep parameters and odor stimulations
| Physostigmine | Placebo | |||
|---|---|---|---|---|
| Odor | Vehicle | Odor | Vehicle | |
| TST (in min) | 46.93 ± 2.95 | 46.17 ± 2.56 | 47.32 ± 3.35 | 43.68 ± 3.73 |
| S1 (in %) | 5.21 ± 1.15 | 5.57 ± 1.28 | 5.82 ± 0.90 | 5.46 ± 0.70 |
| S2 (in %) | 41.37 ± 3.15 | 41.21 ± 2.23 | 46.32 ± 2.66 | 44.20 ± 3.19 |
| S3 (in %)* | 39.71 ± 3.42 | 39.81 ± 3.69 | 27.36 ± 3.18 | 30.44 ± 2.93 |
| S4 (in %) | 10.79 ± 3.58 | 11.39 ± 2.95 | 19.60 ± 3.55 | 18.12 ± 4.51 |
| Wake (in %) | 2.75 ± 1.74 | 1.90 ± 1.77 | 0.86 ± 0.42 | 1.53 ± 1.06 |
| Stimulations | 21.27 ± 0.32 | 20.53 ± 0.73 | 22.36 ± 0.79 | 20.86 ± 0.73 |
TST total sleep time, S1–S4 relative time spent in each sleep stage, Wake relative time spent awake after sleep onset, and number of odor stimulations (means ± s.e.m.). *p = 0.012 for ANOVA main effect “physostigmine/placebo.” No other significant effects of group or condition